Sidley represented Zenas BioPharma, Inc. (Nasdaq: ZBIO) in a license agreement with InnoCare Pharma Limited (HKEX: 09969; SSE: 688428) granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis (MS), including all therapeutic areas other than oncology. Additionally, as a result of the agreement, Zenas secured rights to a novel, oral, IL-17AA/AF inhibitor, and an oral, brain-penetrant, TYK2 inhibitor.
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor with the potential to address compartmentalized inflammation and disease progression in MS.
The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions) and included Nick DeAngelis (M&A and Private Equity) and Jean Qiu and Cassidy Pomeroy-Carter (both Technology and Life Sciences Transactions).
More information about this transaction can be found here.
